

Murray Epstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6174813/publications.pdf>

Version: 2024-02-01

87
papers

6,527
citations

186209

28
h-index

66879

78
g-index

93
all docs

93
docs citations

93
times ranked

5394
citing authors

#	ARTICLE	IF	CITATIONS
1	Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. <i>Hepatology</i> , 1988, 8, 1151-1157.	3.6	1,513
2	Preserving renal function in adults with hypertension and diabetes: A consensus approach. <i>American Journal of Kidney Diseases</i> , 2000, 36, 646-661.	2.1	1,314
3	Renal failure in the patient with cirrhosis. <i>American Journal of Medicine</i> , 1970, 49, 175-185.	0.6	452
4	Renin-Angiotensin System Blockers and the COVID-19 Pandemic. <i>Hypertension</i> , 2020, 75, 1382-1385.	1.3	412
5	Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 940-951.	2.2	376
6	Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension. <i>Annals of Internal Medicine</i> , 2009, 150, 776.	2.0	309
7	Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. <i>American Journal of Kidney Diseases</i> , 2001, 37, 677-688.	2.1	140
8	Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. <i>American Journal of Managed Care</i> , 2015, 21, S212-20.	0.8	123
9	Disparate Effects of Calcium Antagonists on Renal Microcirculation.. <i>Hypertension Research</i> , 1996, 19, 31-36.	1.5	112
10	Aldosterone Blockade: An Emerging Strategy for Abrogating Progressive Renal Disease. <i>American Journal of Medicine</i> , 2006, 119, 912-919.	0.6	109
11	Newer Approaches to Antihypertensive Therapy. <i>Archives of Internal Medicine</i> , 1996, 156, 1969.	4.3	102
12	Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. <i>American Journal of Kidney Diseases</i> , 2005, 45, 2-14.	2.1	100
13	Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. <i>Pharmacological Research</i> , 2016, 113, 585-591.	3.1	91
14	Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. <i>Kidney International</i> , 2012, 81, 955-968.	2.6	85
15	Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. <i>Journal of Hypertension</i> , 2001, 19, 829-842.	0.3	83
16	Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium-Sparing Diuretics. <i>Journal of Clinical Hypertension</i> , 2011, 13, 644-648.	1.0	69
17	The Calcium Antagonist Controversy: The Emerging Importance of Drug Formulation as a Determinant of Risk. <i>American Journal of Cardiology</i> , 1997, 79, 9-19.	0.7	63
18	Aldosterone as a Determinant of Cardiovascular and Renal Dysfunction. <i>Journal of the Royal Society of Medicine</i> , 2001, 94, 378-383.	1.1	56

#	ARTICLE	IF	CITATIONS
19	Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrology Dialysis Transplantation, 2003, 18, 1984-1992.	0.4	53
20	Characterization of Renal Prostaglandin E Responsiveness in Decompensated Cirrhosis: Implications for Renal Sodium Handling. Clinical Science, 1982, 63, 555-563.	1.8	49
21	Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney International Supplements, 2016, 6, 20-28.	4.6	49
22	Atrial Natriuretic Factor and Liver Disease. Hepatology, 1993, 17, 500-513.	3.6	46
23	Statins in the management of dyslipidemia associated with chronic kidney disease. Nature Reviews Nephrology, 2012, 8, 214-223.	4.1	46
24	Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present. American Journal of Nephrology, 2021, 52, 209-216.	1.4	41
25	Resistant Hypertension: Prevalence and Evolving Concepts. Journal of Clinical Hypertension, 2007, 9, 2-6.	1.0	36
26	Lercanidipine. Heart Disease (Hagerstown, Md), 2001, 3, 398-407.	1.3	34
27	Is the failure of SYMPPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?. Journal of the American Society of Hypertension, 2015, 9, 140-149.	2.3	34
28	Evolving concepts in the management of hypertension. Clinical Cardiology, 1995, 18, 3-11.	0.7	29
29	Renal eicosanoids as determinants of renal function in liver disease. Hepatology, 1987, 7, 1359-1367.	3.6	28
30	Hypertension and Chronic Kidney Disease Progression: Why the Suboptimal Outcomes?. American Journal of Medicine, 2012, 125, 1057-1062.	0.6	27
31	Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016. American Journal of Medicine, 2016, 129, 661-666.	0.6	27
32	Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. Expert Opinion on Pharmacotherapy, 2016, 17, 1435-1448.	0.9	26
33	Hypertension in patients with diabetes. Postgraduate Medicine, 2000, 107, 47-60.	0.9	25
34	Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. Lancet Diabetes and Endocrinology, 2015, 3, 993-1003.	5.5	25
35	Aldosterone as a Mediator of Progressive Renal Dysfunction: Evolving Perspectives.. Internal Medicine, 2001, 40, 573-583.	0.3	22
36	Matrix Gla-Protein (MGP) Not Only Inhibits Calcification in Large Arteries But Also May Be Renoprotective: Connecting the Dots. EBioMedicine, 2016, 4, 16-17.	2.7	22

#	ARTICLE	IF	CITATIONS
37	The role of aldosterone in resistant hypertension: Implications for pathogenesis and therapy. <i>Current Hypertension Reports</i> , 2007, 9, 98-105.	1.5	21
38	Review. <i>Renal Failure</i> , 1996, 18, 813-832.	0.8	20
39	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. <i>International Journal of Cardiology</i> , 2016, 216, 46-51.	0.8	20
40	Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. <i>Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension</i> , 2002, 20, S17-23.	0.1	20
41	Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 310-311.	2.0	18
42	Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease. <i>Nature Clinical Practice Nephrology</i> , 2009, 5, 12-13.	2.0	17
43	The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical Trials. <i>Kidney International Reports</i> , 2016, 1, 43-56.	0.4	17
44	Role of a Third Generation Calcium Antagonist in the Management of Hypertension*. <i>Drugs</i> , 1999, 57, 1-10.	4.9	16
45	Hypertension in patients with diabetes. <i>Postgraduate Medicine</i> , 2000, 107, 53-64.	0.9	16
46	Comparative Pharmacokinetics and Pharmacodynamics of Amlodipine in Hypertensive Patients with and without Type II Diabetes Mellitus. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1215-1224.	1.0	13
47	Hyperkalemia as a Constraint to Therapy With Combination Renin-Angiotensin System Blockade: The Elephant in the Room. <i>Journal of Clinical Hypertension</i> , 2009, 11, 55-60.	1.0	13
48	Potassium homeostasis and dyskalemias: the respective roles of renal, extrarenal, and gut sensors in potassium handling. <i>Kidney International Supplements</i> , 2016, 6, 7-15.	4.6	13
49	Resistant Hypertension. <i>Hypertension</i> , 2016, 68, 1073-1080.	1.3	12
50	Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. <i>American Journal of Managed Care</i> , 2016, 22, s311-s324.	0.8	12
51	Natriuretic Effects of Calcium Antagonists in Humans: A Review of Experimental Evidence and Clinical Data. <i>Cardiovascular Drug Reviews</i> , 1991, 9, 398-412.	4.4	11
52	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. <i>American Journal of Medicine</i> , 2021, 134, 166-175.	0.6	11
53	Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 925-927.	5.5	10
54	The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets. <i>Kidney International Supplements</i> , 2022, 12, 48-62.	4.6	10

#	ARTICLE	IF	CITATIONS
55	Recent landmark clinical trials: how do they modify the therapeutic paradigm?. American Journal of Hypertension, 2002, 15, S82-S84.	1.0	9
56	The intersection of mineralocorticoid receptor activation and the FGF23-Klotho cascade: a duopoly that promotes renal and cardiovascular injury. Nephrology Dialysis Transplantation, 2022, 37, 211-221.	0.4	9
57	Volume as a Determinant of Plasma Aldosterone in Anephric Man*. Journal of Clinical Endocrinology and Metabolism, 1978, 46, 309-316.	1.8	8
58	A Podcast Discussing Aldosterone and Mineralocorticoid Receptor Antagonists in 2021: A Paradigm Shift. Diabetes Therapy, 2022, 13, 583-588.	1.2	8
59	Calcium channel blockers and hypertension: Evolving perspectives?1996. Cardiovascular Drugs and Therapy, 1997, 10, 883-891.	1.3	7
60	A forgotten chapter in the history of the renal circulation: the Josep Trueta and Homer Smith intellectual conflict. American Journal of Physiology - Renal Physiology, 2015, 309, F90-F97.	1.3	7
61	Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 455-457.	2.2	7
62	Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists—unmet needs and underserved patient cohorts. Kidney International Supplements, 2022, 12, 69-75.	4.6	7
63	Atrial natriuretic factor and liver disease. Hepatology, 1993, 17, 500-513.	3.6	6
64	Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: an extraordinary paradigm shift. Kidney International Supplements, 2022, 12, 1-6.	4.6	6
65	Review: Relationship between Erythropoietin Administration and Alterations of Renin-Angiotensin-Aldosterone. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, 135-138.	1.0	5
66	Re: “Mortality Attributed to COVID-19 in High-Altitude Populations” by Woolcott and Bergman. High Altitude Medicine and Biology, 2021, 22, 102-104.	0.5	5
67	Microalbuminuria Constitutes a Clinical Action Item for Clinicians in 2021. American Journal of Medicine, 2022, 135, 576-580.	0.6	5
68	Determinants of abnormal renal sodium handling in cirrhosis: a reappraisal. Scandinavian Journal of Clinical and Laboratory Investigation, 1980, 40, 689-694.	0.6	4
69	Renin-Angiotensin-Aldosterone System Inhibition and Mineralocorticoid Receptor Antagonists: The Overriding Importance of Enablers and Dampers. Kidney International Reports, 2021, 6, 869-871.	0.4	4
70	Hepatorenal syndrome: a historical appraisal of its origins and conceptual evolution. Kidney International, 2021, 99, 1321-1330.	2.6	4
71	The Growing Role of Calcium Antagonists in Treating Hypertension in the Elderly. The American Journal of Geriatric Cardiology, 2000, 9, 42-48.	0.7	3
72	Role of Aldosterone Blockade in the Management of Hypertension and Cardiovascular Disease. , 2004, 143, 90-104.		3

#	ARTICLE	IF	CITATIONS
73	John P. Merrill. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 2-8.	2.2	3
74	A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+binder: â€˜the forbidden fruitâ€™. European Heart Journal, 2016, 37, 3130-3134.	1.0	3
75	Avoiding the termination of ACTT. European Heart Journal, 2020, 41, 4468-4470.	1.0	3
76	Calcium Antagonists and the Kidney.. Tohoku Journal of Experimental Medicine, 1992, 166, 123-134.	0.5	2
77	Hyperkalemia: current concepts and emerging therapeutic options. Kidney International Supplements, 2016, 6, 1-2.	4.6	2
78	Introduction to focused section on calcium antagonists and the kidney. Cardiovascular Drugs and Therapy, 1990, 4, 1317-1318.	1.3	0
79	Evolving role of calcium antagonists in the management of hypertension. Medical Clinics of North America, 2004, 88, 149-165.	1.1	0
80	Highlights from International Congress. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 61-72.	1.0	0
81	Atorvastatin Does Not Induce Glomerular or Tubular Dysfunction Even at High Doses. Journal of the Cardiometabolic Syndrome, 2007, 2, 163-167.	1.7	0
82	The future for renal denervation depends on embracing the lessons learned from our previous studies. Journal of the American Society of Hypertension, 2016, 10, 396-398.	2.3	0
83	Josep Trueta and Renal Sympathetic Activation. European Heart Journal, 2020, 41, 4543-4545.	1.0	0
84	Norman K. Hollenberg. Hypertension, 2020, 76, 288-290.	1.3	0
85	Defining the Optimal Dialysis Regimen for Improving Left Ventricular Structure and Function: An Urgent Need. Journal of Cardiac Failure, 2020, 26, 492-493.	0.7	0
86	Norman K. Hollenberg, MD PhD (1936â€™2020). European Heart Journal, 2020, 41, 1540-1541.	1.0	0
87	Calcium Antagonists: Still Appropriate as First Line Antihypertensive Agents. American Journal of Hypertension, 0, , .	1.0	0